LUND, SWEDEN, Oct. 27, 2023 /PRNewswire/ -- Immunovia AB
(publ), reg. no. 556730-4299 (the "Company"), hereby gives
notice that an extraordinary general meeting will take place on
Tuesday 21st November 2023
at 10.00 in the Company's offices at Medicon Village, Scheeletorget
1, Lund. Registration to the
extraordinary general meeting starts at 09:45.
Notice/Right to participate at the general
meeting
A shareholder who wishes to participate in the extraordinary
general meeting must (i) be recorded in the share register prepared
by Euroclear Sweden AB relating to the circumstances on the
13th November 2023,
and (ii) notify its intention to participate in the
extraordinary general meeting no later than the 15th
November 2023, either by post
to "Bolagsstämma", Immunovia AB, Scheelevägen 2, 223 63
Lund, Sweden or via email
to bolagsstamma@immunovia.com. A participation notice shall contain
name and personal identity number or corporate registration number,
address, telephone number, registered shareholding and number of
attending advisors, if any (not more than 2).
To be entitled to participate in the extraordinary general
meeting, a shareholder whose shares are held in the name of a
nominee must register its shares in its own name so that the
shareholder is recorded in the share register as of the
13th November 2023. Such
registration may be temporary (so-called voting right registration)
and is requested from the nominee in accordance with the nominee's
procedures and such time in advance as the nominee determines.
Voting right registrations completed no later than the
15th November 2023 will be
taken into account when preparing the share register.
Authorisation documents
Shareholders who are represented by proxy must issue a written,
dated proxy for the representative. Such proxy forms are available
at https://immunovia.com/sv/bolagsstamma/. The proxy should be sent
to the Company in accordance with the above, together with the
participation notice. If the proxy is issued by a legal entity, a
copy of the certificate of registration or an equivalent
certificate of authority must be submitted.
Proposed agenda
- Opening of the meeting and election of a chair for the
meeting
- Preparation and approval of voting list
- Election of person(s) to approve the minutes
- Determination of whether the meeting has been duly
convened
- Approval of the agenda
- Election of board members
- Determination of fees for the board and
committees
- Resolution on adoption of an equity incentive program for
the Company's management and key personnel
- Resolution on adoption of an equity incentive program for
the Company's board of directors
- Closing of the meeting
Resolution proposals at Immunovia AB (publ)'s
extraordinary general meeting
§ 1 Opening of the meeting and election of a chair for the
meeting
The nomination committee for the 2024 Annual General Meeting
consists of Carl Borrebaeck (representing himself), Mats Leifland
(appointed by Mats Ohlin),
Sara Ek (representing herself) and
Peter Høngaard Andersen (chair of the board). Sara Ek has served as chair of the nomination
committee.
The nomination committee proposes that Fredrik Önnerfors should
be elected as chair for the meeting or, if he is not able to
participate at the meeting, another person proposed by the
nomination committee.
§ 6 Election of board members
The nomination committee proposes to appoint two additional
board members, and that the number of board members for the period
ending on the next annual general meeting shall be six, with no
deputy members. Against this background, the nomination committee
proposes that Melissa Farina and
Valerie Bogdan-Powers shall be
elected as new board members.
In the event that the general meeting resolves to appoint
Melissa Farina and Valerie Bogdan-Powers as new board members, the
board will consist of Peter Høngaard Andersen (chair), Hans Johansson, Michael Löfman, Martin Møller,
Melissa Farina and Valerie Bogdan-Powers.
Melissa Farina
Melissa Farina is a
result-oriented leader with experience from both start-up and
Fortune 500 companies. She is known for her rapid and efficient
execution of business strategies and ability to drive business
improvements. She has more than 20 years of experience in the life
science sector in positions with responsibility for accounting,
financing, investor relations, and sales and has an extensive
network in the US financial world. Her experience spans e.g.,
positions as VP of financing and investor relations in LivaNova
(2010 - 2021), later interim CEO; CFO in Neuspera Medical (2021 -
2023); and her current position as CFO in Conformal Medical Inc
(2023 - present). Earlier, she was general account manager in
Becton Dickinson (2004 - 2010) and
internal auditor in United Technologies Corp (2001 - 2004).
Melissa Farina holds an MBA from
Rice University, Houston, Texas.
Melissa Farina is independent in
relation to the Company, the Company's management, and the
Company's major shareholders. She holds no shares in the
Company.
Valerie
Bogdan-Powers
Valerie Bogdan-Powers is a high
energy executive with 35 years' experience in launching new
businesses, growing mature businesses and maximizing value of
mature businesses in multiple business models. She leverages
strategic leadership and analytic skills with the intuitive ability
to motivate teams and people to exceed business results. Her
impressive experience in the spans various marketing, sales and
management positions, with multiple recent roles in health care and
insurance. For example, at Procter & Gamble Pharmaceuticals,
(2006 - 2010), Val served as Marketing Director and led the
company's efforts to secure reimbursement for P&G's
pharmaceutical products. She later led Horan Health, a health
insurance brokerage, as President before becoming President of Hub
Heartland in Hub International. Valerie
Bogdan-Powers holds a BA in American History, Harvard
University.
Valerie Bogdan-Powers is
independent in relation to the Company, the Company's management,
and the Company's major shareholders. She holds no shares in the
Company.
§ 7 Determination of fees for the board and
committees
The Annual General Meeting 2023 resolved that remuneration for
work within the Board for the period until the end of the next
annual general meeting should be SEK
550,000 for the Chair and SEK
240,000 each for the other Board members. Furthermore, the
Annual General Meeting 2023 resolved that the remuneration to the
Chair of the Audit Committee and the Remuneration Committee shall
be SEK 50,000 and the other members
of the said committees shall be remunerated with SEK 30,000. In view of the proposed equity
incentive program for the Board, the Nomination Committee proposes
that the remuneration resolved by the Annual General Meeting 2023
to the Board members elected by the Annual General Meeting 2023 for
the period from their election to the Extraordinary General Meeting
shall be paid in proportion to the length of their respective terms
of office.
The Nomination Committee proposes that the remuneration for work
within Board to each of the current Board members elected by the
Annual General Meeting 2023 and to each of the Board members to be
newly elected by the Extraordinary General Meeting shall be
SEK 180,000 (on an annual basis) and
for the Chair SEK 420,000 (on an
annual basis), and that the remuneration to these members for the
period from the time their election takes effect until the end of
the next Annual General Meeting shall be paid in proportion to the
length of their respective terms of office.
It is further proposed that the Chair of the Audit, Science and
Remuneration Committee to be remunerated with SEK 40,000 and other members of said committees
to be remunerated with SEK 25,000 (on
an annual basis), and that the remuneration to these members for
the period from the time their election takes effect until the end
of the next Annual General Meeting shall be paid in proportion to
the length of their respective terms of office. Furthermore, it is
proposed that the Board members are compensated for reasonable
travel expenses in accordance with the company's travel
policy.
§ 8 Resolution on adoption of an equity incentive program for
the Company's management and key personnel
The Board of Directors of Immunovia AB (publ) proposes the
introduction of an incentive program for the Company's management
and key personnel (including employees and consultants of
Immunovia, Inc.) in accordance with the following.
The Board of Directors proposes that the extraordinary general
meeting resolves to implement an incentive program for management
and key personnel (including employees and consultants) in
Immunovia and Immunovia, Inc. ("ESOP 2023") in accordance
with items 8a - 8c below.
The resolutions under items 8a - 8b below are proposed to be conditional upon each
other. Should the majority requirement for item 8b below not be met, the Board of Directors
proposes that Immunovia shall be able to enter into an equity swap
agreement with a third party in accordance with item 8c below and
resolutions under items 8a and 8c shall then be conditional upon
each other.
ESOP 2023 is a program under which the participants will be
granted stock options (so called non-qualified in the United States) to purchase shares in
Immunovia ("Options"). The Board of Directors proposes that
a maximum of 1,934,463 Options may be allocated to the
participants.
8a - Adoption of a long-term incentive program for the
Company's management and key personnel
The rationale for the proposal
ESOP 2023 is intended for members of management and key
personnel (including employees and consultants) in Immunovia AB and
Immunovia, Inc. The Board of Directors of Immunovia believes that
an equity-based incentive program in the form of stock options is a
central part of an attractive and competitive remuneration package
in order to attract, retain and motivate competent members of
management and key personnel (including employees and consultants)
in Immunovia and Immunovia, Inc., and to focus the participants on
delivering exceptional performance which contributes to value
creation for all shareholders. The proposed program is designed to
match US market practices, reflecting the importance of attracting
US-based personnel.
Conditions for Options
The following conditions shall apply for the Options.
- The Options shall be granted at no cost to the
participants.
- The Board of Directors shall resolve upon the allocation of
Options upon commencement of employment and from time to time
during employment based upon performance up until Immunovia's
annual general meeting 2024 (with each respective granting falling
on a "Grant Date").
- Each Option entitles the holder to purchase one share in
Immunovia for a pre-determined exercise price. The exercise price
will correspond to 100 percent of the volume weighted average price
of the Immunovia share on Nasdaq Stockholm during the five (5)
trading days preceding the Grant Date.
- The Options are subject to a four-year cliff vesting, with 25
percent vesting after first year of commencement of
employment/consultancy (or grant, as applicable) and remaining 75
percent vesting in equal monthly instalments thereafter. For
allocations to existing employees, vesting could thus take place
already upon grant if the employees have been employed for more
than one year already upon grant.
- The Options may be exercised from vesting up until the ten-year
anniversary of the Grant Date. The Board of Directors considers
that a time period from the Grant Date until exercise being shorter
than three years is appropriate since the proposed program is key
for the Company's ability to attract, retain and motivate competent
key persons and top talents especially in the United States and that the proposed
program is based on an analysis of, and in line with, the current
market practice for long-term incentive programs in the United
States.
- The number of Options shall be subject to Swedish customary
re-calculation rules, for example in the event that changes occur
in Immunovia' equity capital structure, such as a bonus issue,
merger, rights issue, share split or reverse share split, reduction
of the share capital or similar measures.
- The Options are non-transferable and may not be
pledged.
- The Options may be granted by the parent company as well as any
other company within the Immunovia group.
- In the event of a public tender offer, merger, acquisition or
other similar transaction which results in a shareholder (alone or
together with closely-related parties) reaching a shareholding in
Immunovia of in total at least 30 percent of the votes, the Options
will vest immediately and in their entirety in case the employment
or assignment is terminated within 12 months following completion
of such a transaction, provided that the termination is carried out
by Immunovia without cause.
Allocation
The right to receive Options shall accrue to employees and
consultants of Immunovia AB and Immunovia, Inc. The Board of
Directors may grant Options upon commencement of employment and
from time to time during employment based on performance up until
Immunovia's annual general meeting 2024. The maximum number of
Options that may be allocated to the participants under the ESOP
2023 program is 1,934,463 and the maximum allocation per individual
shall be 967,232 Options.
Preparation, administration and the right to amend the terms
of the Options
The Board of Directors is responsible for preparing the detailed
terms and conditions of ESOP 2023, in accordance with the
above-mentioned terms and guidelines. To this end, the Board of
Directors shall be entitled to make adjustments to meet foreign
regulations or market conditions, including resolving on cash or
other settlement if deemed favorable for Immunovia based on foreign
tax regulations. The Board of Directors may also make other
adjustments if significant changes in Immunovia or its environment
would result in a situation where the existing terms and conditions
of ESOP 2023 no longer serve their purpose.
Preparation of the proposal
ESOP 2023 has been initiated and prepared by the Board of
Directors of Immunovia together with external counsel including US
legal counsel. It has been structured based on an evaluation of
prior incentive programs and market practice in the United States in order to attract, retain
and motivate employees and consultants in the United
States.
Dilution
Subject to certain recalculation conditions, the maximum number
of shares that may be issued to participants under ESOP 2023 is
1,934,463 shares and, in addition, a maximum of 662,771 shares may
be issued in order to cover any social security costs due to ESOP
2023, i.e. a maximum of 2,597,234 shares, which corresponds to a
dilution of approximately 5.4 percent on a fully diluted basis.
Taking into account also the shares which may be issued pursuant to
warrants under the Company's outstanding incentive programs as well
as the proposed long-term incentive program for the Company's board
of directors, the maximum dilution amounts to approximately 6.7
percent on a fully diluted basis.
The dilution is expected to have a marginal effect on the
Company's key performance indicator "Earnings (loss) per
share".
Information about Immunovia' existing incentive programs can be
found in the Company's annual report 2022 in note 10.
Scope and costs of the program
ESOP 2023 will be accounted for in accordance with "IFRS 2 -
Share-based payments". IFRS 2 stipulates that the Options shall be
expensed as personnel costs over the vesting period. Personnel
costs in accordance with IFRS 2 do not affect the Company's cash
flow. Social security costs will be expensed in the income
statement according to UFR 7 during the vesting
period.
Assuming a share price at the time of allocation of Options of
SEK 0.87 and that all Options are
allocated up-front under the assumptions set out under "Dilution"
above, the cost for Immunovia according to IFRS 2 is estimated to
be approximately KSEK 619 before tax (non-cash flow). The social
security costs over the vesting period are estimated to be approxi
mately a total of KSEK 198, based on the above assumptions, that
all Options are fully vested, based on a ten-year period from grant
until the expiry date of the Options and social security costs of
31.4 percent. It is envisaged that the social security costs
associated with ESOP 2023 will be covered by the cash received from
the participants at exercise of Options. If necessary, social
security costs will be covered by hedging measures through the
issue of warrants (see item 8b below)
which would be exercised by a financial intermediary in connection
with the exercise of the Options. In either case, the social
security costs associated with ESOP 2023 will be fully covered and
will hence not affect the Company's cash flow.
The total cost of ESOP 2023, including all social security
costs, is estimated to amount to approximately SEK 817,000 under the above assumptions. However,
the actual costs are likely to be lower, since not all participants
are Swedish residents and social security costs will therefore not
apply to all participants.
The costs associated with ESOP 2023 are expected to have a
marginal effect on the Company's key performance
indicators.
Delivery of shares under ESOP 2023
In order to ensure the delivery of shares under ESOP 2023 and if
necessary for hedging of social security costs, the Board of
Directors proposes that the extraordinary general meeting resolves
to issue and use warrants in accordance with item 8b below.
8b - Issue of
warrants
In order to ensure the delivery of shares under ESOP 2023, and
for hedging of social security costs, the Board of Directors
proposes that the extraordinary general meeting resolves to issue
not more than 2,597,234 warrants, whereby the Company's share
capital could be increased by not more than SEK 129,861.7.
The right to subscribe for the warrants shall, with deviation
from the shareholders' pre-emptive rights, only be granted the
wholly owned subsidiary Immunovia Incentive AB (the
"Subsidiary"). The reason for the deviation from the
shareholders' pre-emptive rights is the implementation of ESOP
2023. The Subsidiary shall be entitled to transfer the warrants to
participants or a financial intermediary in connection with
exercise.
The warrants shall be issued free of charge and shall be
subscribed for on a subscription list no later than 31 December
2023. The Board of Directors may extend the subscription period.
The exercise price for subscription for shares based on the
warrants shall correspond to the share's quota
value.
The full terms and conditions for the warrants are presented in
the complete proposal which is kept available to the shareholders
in accordance with the below.
8c - Equity swap agreement with a third
party
Should the majority requirement for item 8b above not be met, the Board of Directors
proposes that the extraordinary general meeting resolves that ESOP
2023 instead shall be hedged through an equity swap agreement with
a third party on terms in accordance with market practice, whereby
the third party in its own name shall be entitled to acquire and
transfer shares of Immunovia to the participants.
Majority rules
The implementation of the Board of Directors' proposals under
item 8b above requires approval of at
least nine tenths (9/10) of the shares represented and votes cast
at the extraordinary general meeting.
§ 9 Resolution on adoption of an equity incentive program for
the Company's board of directors
The Nomination Committee of Immunovia AB (publ) proposes the
introduction of an incentive program for the Company's board of
directors in accordance with the following.
The Nomination Committee proposes that the extraordinary general
meeting resolves to implement an incentive program for board of
directors in Immunovia ("Board ESOP 2023") in accordance
with items 9a - 9c below.
The resolutions under items 9a - 9b below are proposed to be conditional upon each
other. Should the majority requirement for item 9b below not be met, the Nomination Committee
proposes that Immunovia shall be able to enter into an equity swap
agreement with a third party in accordance with item 9c below and
resolutions under items 9a and 9c shall then be conditional upon
each other.
Board ESOP 2023 is a program under which the participants will
be granted stock options (so called non-qualified in the United States) to purchase shares in
Immunovia ("Options"). The Nomination Committee proposes
that a maximum of 483,616 Options may be allocated to the
participants.
9a - Adoption of a long-term incentive program for the
Company's board of directors
The rationale for the proposal
Board ESOP 2023 is intended for board of directors in Immunovia
AB. The Nomination Committee of Immunovia believes that an
equity-based incentive program in the form of stock options is a
central part of an attractive and competitive remuneration package
in order to attract, retain and motivate competent board members in
Immunovia and to focus the participants on delivering exceptional
performance which contributes to value creation for all
shareholders. The proposed program is designed to match US market
practices, reflecting the importance of attracting US-based board
members.
Conditions for Options
The following conditions shall apply for the Options.
- The Options shall be granted at no cost to the
participants.
- The Options shall be allocated as soon as practicable following
the approval by the extraordinary general meeting up until
Immunovia's annual general meeting 2024 (with each respective
granting falling on a "Grant Date").
- Each Option entitles the holder to purchase one share in
Immunovia for a pre-determined exercise price. The exercise price
will correspond to 100 percent of the volume weighted average price
of the Immunovia share on Nasdaq Stockholm during the five (5)
trading days preceding the Grant Date.
- The Options shall vest from allocation up to Immunovia's annual
general meeting 2024 provided that the holder is still a board
member of Immunovia on said date.
- Participants shall enter into option agreements with
Immunovia.
- The Options may be exercised from vesting up until the ten-year
anniversary of the Grant Date. Thus, the earliest date of exercise
may be shorter than three years from the Grant Date. The Nomination
Committee considers, based on an evaluation of prior incentive
programs and market practice in the
United States, that such terms are necessary in order to
attract the right expertise given the Company's business
plan.
- The number of Options shall be subject to Swedish customary
re-calculation rules, for example in the event that changes occur
in Immunovia' equity capital structure, such as a bonus issue,
merger, rights issue, share split or reverse share split, reduction
of the share capital or similar measures.
- The Options are non-transferable and may not be
pledged.
- The Options may be granted by the parent company as well as any
other company within the Immunovia group.
- In the event of a public tender offer, merger, acquisition or
other similar transaction which results in a shareholder (alone or
together with closely-related parties) reaching a shareholding in
Immunovia of in total at least 30 percent of the votes, the Options
will vest immediately and in their entirety in case the assignment
as board member is terminated prior to the annual general meeting
2024, provided that the board member is willing to continue the
assignment during this period.
- The Options shall otherwise be subject to the terms set forth
in the separate agreements with the participants and the detailed
terms for Board ESOP 2023.
Allocation
The right to receive Options shall accrue to board members of
Immunovia AB. The Options shall be granted as soon as practicable
to the board members following approval by the extraordinary
general meeting up until Immunovia's annual general meeting 2024.
The maximum number of Options that may be allocated to the
participants under the Board ESOP 2023 program is 483,616 and shall
be allocated in accordance with the following:
- 138,176 Options shall be allocated to the Chair of the board of
directors; and
- 69,088 Options shall be allocated to each of the board
members.
The number of Options to each of the board members is based on
the condition that the board of the Company consists of six board
members (including the board members proposed to the extraordinary
general meeting). The number of Options under the Board ESOP 2023
will thus be reduced accordingly if the number of board members is
less than six.
Preparation, administration and the right to amend the terms
of the Options
The Nomination Committee is responsible for preparing the
detailed terms and conditions of Board ESOP 2023, in accordance
with the above-mentioned terms and guidelines. To this end, the
Nomination Committee shall be entitled to make adjustments to meet
foreign regulations or market conditions, including resolving on
cash or other settlement if deemed favorable for Immunovia based on
foreign tax regulations. The Nomination Committee may also make
other adjustments if significant changes in Immunovia or its
environment would result in a situation where the existing terms
and conditions of Board ESOP 2023 no longer serve their
purpose.
Preparation of the proposal
Board ESOP 2023 has been initiated and prepared by the
Nomination Committee of Immunovia together with external counsel
including US legal counsel. It has been structured based on an
evaluation of prior incentive programs and market practice in
the United States in order to
attract, retain and motivate board members.
Dilution
Subject to certain recalculation conditions, the maximum number
of shares that may be issued to participants under Board ESOP 2023
is 483,616 shares and, in addition, a maximum of 165,693 shares may
be issued in order to cover any social security costs due to Board
ESOP 2023, i.e. a maximum of 649,309 shares, which corresponds to a
dilution of approximately 1.4 percent on a fully diluted basis.
Taking into account also the shares which may be issued pursuant to
warrants under the Company's outstanding incentive programs as well
as the proposed long-term incentive program for the Company's
employees and consultants, the maximum dilution amounts to
approximately 6.7 percent on a fully diluted basis.
The dilution is expected to have a marginal effect on the
Company's key performance indicator "Earnings (loss) per
share".
Information about Immunovia' existing incentive programs can be
found in the Company's annual report 2022 in note 10.
Scope and costs of the program
Board ESOP 2023 will be accounted for in accordance with "IFRS 2
- Share-based payments". IFRS 2 stipulates that the Options shall
be expensed as personnel costs over the vesting period. Personnel
costs in accordance with IFRS 2 do not affect the Company's cash
flow. Social security costs will be expensed in the income
statement according to UFR 7 during the vesting
period.
Assuming a share price at the time of allocation of Options of
SEK 0.87 and that all Options are
allocated up-front under the assumptions set out under "Dilution"
above, the cost for Immunovia according to IFRS 2 is estimated to
be approximately KSEK 155 before tax (non-cash flow). The social
security costs over the vesting period are estimated to be
approximately a total of KSEK 50, based on the above assumptions,
that all Options are fully vested, a vesting period for all Options
up until Immunovia's annual general meeting 2024 and social
security costs of 31.4 percent. It is envisaged that the social
security costs associated with Board ESOP 2023 will be covered by
the cash received from the participants at exercise of Options. If
necessary, social security costs will be covered by hedging
measures through the issue of warrants (see item 9b below) which would be exercised by a financial
intermediary in connection with the exercise of the Options. In
either case, the social security costs associated with Board ESOP
2023 will be fully covered and will hence not affect the Company's
cash flow.
The total cost of Board ESOP 2023, including all social security
costs, is estimated to amount to approximately SEK 204,000 under the above assumptions. However,
the actual costs are likely to be lower, since not all participants
are Swedish residents and social security costs will therefore not
apply to all participants.
The costs associated with Board ESOP 2023 are expected to have a
marginal effect on the Company's key performance
indicators.
Delivery of shares under Board ESOP 2023
In order to ensure the delivery of shares under Board ESOP 2023
and if necessary for hedging of social security costs, the
Nomination Committee proposes that the extraordinary general
meeting resolves to issue and use warrants in accordance with item
9b below.
9b - Issue of
warrants
In order to ensure the delivery of shares under Board ESOP 2023,
and for hedging of social security costs, the Nomination Committee
proposes that the extraordinary general meeting resolves to issue
not more than 649,309 warrants, whereby the Company's share capital
could be increased by not more than SEK
32,465.45.
The right to subscribe for the warrants shall, with deviation
from the shareholders' pre-emptive rights, only be granted the
wholly owned subsidiary Immunovia Incentive AB (the
"Subsidiary"). The reason for the deviation from the
shareholders' pre-emptive rights is the implementation of Board
ESOP 2023. The Subsidiary shall be entitled to transfer the
warrants to participants or a financial intermediary in connection
with exercise.
The warrants shall be issued free of charge and shall be
subscribed for on a subscription list no later than 31 December
2023. The Board of Directors may extend the subscription period.
The exercise price for subscription for shares based on the
warrants shall correspond to the share's quota
value.
The full terms and conditions for the warrants are presented in
the complete proposal which is kept available to the shareholders
in accordance with the below.
9c - Equity swap agreement with a third
party
Should the majority requirement for item 9b above not be met, the Nomination Committee
proposes that the extraordinary general meeting resolves that Board
ESOP 2023 instead shall be hedged through an equity swap agreement
with a third party on terms in accordance with market practice,
whereby the third party in its own name shall be entitled to
acquire and transfer shares of Immunovia to the
participants.
Majority rules
The implementation of the Nomination Committee's proposals under
item 9b above requires approval of at
least nine tenths (9/10) of the shares represented and votes cast
at the extraordinary general meeting.
Number of shares and votes
As per the date of this notice, there are a total of 45,287,498
shares in the Company, each share representing one vote. The
Company does not hold any of its own shares.
Documents
All documentation for the general meeting, including a proxy
form, will be available at the Company and posted on the Company's
website https://immunovia.com/sv/bolagsstamma/ no later than three
weeks prior to the extraordinary general meeting. Copies of the
documents will be sent upon request to shareholders providing their
address to the Company and will be available at the general
meeting.
Information at the extraordinary general
meeting
The board and the CEO shall, if any shareholder so requests and
the board believe that it can be done without material harm to the
Company, provide information regarding circumstances that may
affect the assessment of an item on the agenda and the Company's
relation to other companies within the group.
Processing of personal data
For information on how your personal data is processed, see the
privacy notice available on Euroclear's webpage,
https://www.euroclear.com/dam/ESw/Legal/Privacy%20notice%20BOSS%20-%20final%20220324.pdf.
Lund in October 2023
Immunovia AB (publ)
The board of directors
For more information, please contact:
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl, CFO
karin.almqvist.liwendahl@immunovia.com
+46 70 911 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to
increase survival rates for patients with pancreatic cancer through
early detection. Immunovia is focused on the development and
commercialization of simple blood-based testing to detect proteins
and antibodies that indicate a high-risk individual has developed
pancreatic cancer.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups to make its test
available to individuals at increased risk for pancreatic
cancer.
USA is the world's largest
market for detection of pancreatic cancer. The company estimates
that in the USA, 1.8 million
individuals are at high-risk for pancreatic cancer and could
benefit from annual surveillance testing.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com
CONTACT:
The following files are available for download:
|
https://mb.cision.com/Main/13121/3863976/2390429.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/convening-notice---extraordinary-general-meeting-in-immunovia-ab-publ-301969900.html